Help us: Donate
Follow us on:
×

Menu

Back

Tag: Gensight Biologics

December 11, 2020
A team of researchers, including Dr. Patrick Yu-Wai-Man from the University of Cambridge and Dr. José-Alain Sahel from the University of Pittsburgh and Institut de la Vision, Paris, has successfully treated 37 participants suffering from Leber hereditary optic neuropathy (LHON). A landmark trial for mitochondrial gene therapy The results of this phase 3 clinical trial...
Eye
October 09, 2019
GenSight Biologics has recently released data showing the effectiveness of GS010, the company's gene therapy for Leber Hereditary Optic Neuropathy (LHON), a mitochondrial disease that can lead to blindness. Like in previous studies, this therapy had a bilateral effect. Gene Therapy In LHON, the mitochondrial protein ND4 is poorly expressed through mitochondrial DNA (mtDNA). GS010...
June 21, 2019
Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT). A trial with damagingly positive results Gensight Biologics, a company researching - among other things - the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research...